Sydney Lupkin, NPR's pharmaceutical correspondent, dives deep into revolutionary changes in schizophrenia treatment. After decades of relying on dopamine-focused therapies, a newly FDA-approved drug targets muscarinic receptors, which could reduce brutal side effects. Sydney explores the unexpected origins of this breakthrough, the challenges surrounding new medication accessibility, and the hopeful stories of those navigating these changes. This discussion sheds light on a future where schizophrenia treatments may become more effective and compassionate.

Sydney Lupkin, NPR's pharmaceuticals correspondent, dives into the captivating world of TikTok's influence on healthcare marketing. She discusses the rise of misleading health ads and the need for transparency, particularly around weight loss drugs. The conversation critiques the use of pop culture in promoting medications and explores the complexities of telehealth services on social media. With humor, Candice and Kate share early internet memories while emphasizing consumer vigilance in navigating the modern pharmaceutical landscape rife with scams.

White House correspondent Tamara Keith, White House reporter Deepa Shivaram, and Pharmaceuticals correspondent Sydney Lupkin discuss President Biden's plan to lower drug costs through negotiation, including the first 10 drugs for negotiation, barriers to lowering drug costs, and the potential impact on Medicare spending, support for negotiating drug prices, opposition from drug companies, and the plan's potential impact on different groups.